Prasad Suyash's Form 4 filing
Taysha Gene Therapies, Inc. (TSHA) · filed Jul 1, 2021
- Accession no.
- 0001209191-21-044563
- Filed
- Jul 1, 2021
- Trade date
- Jun 29-Jul 1, 2021
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 7 non-derivative transactions and 0 derivative transactions. Open-market sales total $1.79M. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Prasad SuyashCIK 0001679129 | Officer (CMO and Head of R&D) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jun 29, 2021 | Common Stock | SSaleDisposed | −35,056 | $23.74 | −$832,229.44 | 637,533 | Direct | |
| Jun 29, 2021 | Common Stock | SSaleDisposed | −3,862 | $24.46 | −$94,464.52 | 633,671 | Direct | |
| Jun 29, 2021 | Common Stock | SSaleDisposed | −300 | $25.19 | −$7,557 | 633,371 | Direct | |
| Jun 30, 2021 | Common Stock | SSaleDisposed | −13,374 | $21.42 | −$286,471.08 | 619,997 | Direct | |
| Jun 30, 2021 | Common Stock | SSaleDisposed | −6,202 | $22.44 | −$139,172.88 | 613,795 | Direct | |
| Jun 30, 2021 | Common Stock | SSaleDisposed | −500 | $23.70 | −$11,850 | 613,295 | Direct | |
| Jul 1, 2021 | Common Stock | SSaleDisposed | −19,706 | $21.12 | −$416,190.72 | 593,589 | Direct |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.